Skip to main content
Premium Trial:

Request an Annual Quote

MDx Firm Multiplicom Raises $7.3M

NEW YORK (GenomeWeb News) – Multiplicom has raised €5.5 million ($7.3 million) to support further development of its molecular diagnostic tests and expansion of its business.

Flemish investment firm PMV, RMM (Rudi Mariën) and Qbic ARKIV Fund were new investors in the round. Existing investors including Belgian venture capital firm Gimv, Gimv-managed Biotechfonds Vlaanderen, and life science research institute VIB continue to support Multiplicom, it said, adding VIB will make an investment in kind.

The financing will go toward development of the company's tests, as well as validation studies, and expansion of its European sales channels.

In the spring of 2011 Multiplicom raised $3 million.

Founded in 2010 as a spinout of the University of Antwerp and VIB, the Belgian molecular diagnostics company currently has test kits for cystic fibrosis, bowel cancer, heart failure, kidney disease, and muscle disease available for research-use only.

This year, Multiplicom plans on launching a series of kits for detecting DNA mutations in cancerous tissue that would allow physicians to determine the most appropriate treatments for patients.

"This capital injection will allow us to carry out our ambitious plan to develop innovative molecular diagnostic kits and to remain at the forefront of European businesses in this new branch of medicine," Multiplicom CEO Dirk Pollet said in a statement.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.